• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

筛选出的针对未糖基化表皮生长因子受体变异体Ⅲ(EGFRvIII)胞外域的适配体,经细胞内递送后,可减少膜结合型EGFRvIII并诱导细胞凋亡。

Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis.

作者信息

Liu Yingmiao, Kuan Chien-Tsun, Mi Jing, Zhang Xiuwu, Clary Bryan M, Bigner Darell D, Sullenger Bruce A

机构信息

Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.

出版信息

Biol Chem. 2009 Feb;390(2):137-44. doi: 10.1515/BC.2009.022.

DOI:10.1515/BC.2009.022
PMID:19040357
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3816755/
Abstract

Epidermal growth factor receptor variant III (EGFRvIII) is a glycoprotein uniquely expressed in glioblastoma, but not in normal brain tissues. To develop targeted therapies for brain tumors, we selected RNA aptamers against the histidine-tagged EGFRvIII ectodomain, using an Escherichia coli system for protein expression and purification. Representative aptamer E21 has a dissociation constant (Kd) of 33x10(-9) m, and exhibits high affinity and specificity for EGFRvIII in ELISA and surface plasmon resonance assays. However, selected aptamers cannot bind the same protein expressed from eukaryotic cells because glycosylation, a post-translational modification present only in eukaryotic systems, significantly alters the structure of the target protein. By transfecting EGFRvIII aptamers into cells, we find that membrane-bound, glycosylated EGFRvIII is reduced and the percentage of cells undergoing apoptosis is increased. We postulate that transfected aptamers can interact with newly synthesized EGFRvIII, disrupt proper glycosylation, and reduce the amount of mature EGFRvIII reaching the cell surface. Our work establishes the feasibility of disrupting protein post-translational modifications in situ with aptamers. This finding is useful for elucidating the function of proteins of interest with various modifications, as well as dissecting signal transduction pathways.

摘要

表皮生长因子受体变体III(EGFRvIII)是一种仅在胶质母细胞瘤中表达而在正常脑组织中不表达的糖蛋白。为了开发针对脑肿瘤的靶向治疗方法,我们使用大肠杆菌系统进行蛋白质表达和纯化,筛选针对组氨酸标签化EGFRvIII胞外结构域的RNA适体。代表性适体E21的解离常数(Kd)为33×10(-9)m,并且在ELISA和表面等离子体共振分析中对EGFRvIII表现出高亲和力和特异性。然而,所选适体不能结合真核细胞表达的相同蛋白质,因为糖基化(仅存在于真核系统中的一种翻译后修饰)会显著改变靶蛋白的结构。通过将EGFRvIII适体转染到细胞中,我们发现膜结合的、糖基化的EGFRvIII减少,并且细胞凋亡百分比增加。我们推测转染的适体可以与新合成的EGFRvIII相互作用,破坏正常糖基化,并减少到达细胞表面的成熟EGFRvIII的量。我们的工作确立了用适体原位破坏蛋白质翻译后修饰的可行性。这一发现对于阐明具有各种修饰的感兴趣蛋白质的功能以及剖析信号转导途径很有用。

相似文献

1
Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis.筛选出的针对未糖基化表皮生长因子受体变异体Ⅲ(EGFRvIII)胞外域的适配体,经细胞内递送后,可减少膜结合型EGFRvIII并诱导细胞凋亡。
Biol Chem. 2009 Feb;390(2):137-44. doi: 10.1515/BC.2009.022.
2
DNA aptamers that target human glioblastoma multiforme cells overexpressing epidermal growth factor receptor variant III in vitro.体外靶向人表皮生长因子受体变体 III 过表达的多形性胶质母细胞瘤的 DNA 适体。
Acta Pharmacol Sin. 2013 Dec;34(12):1491-8. doi: 10.1038/aps.2013.137.
3
Pyrene-Modified DNA Aptamers with High Affinity to Wild-Type EGFR and EGFRvIII.具有高亲和力的吡咯并[2,1-f][1,2,4]三嗪修饰的 DNA 适体对野生型 EGFR 和 EGFRvIII。
Nucleic Acid Ther. 2020 Jun;30(3):175-187. doi: 10.1089/nat.2019.0830. Epub 2020 Jan 28.
4
Cell-SELEX aptamer for highly specific radionuclide molecular imaging of glioblastoma in vivo.用于胶质母细胞瘤体内高特异性放射性核素分子成像的细胞指数富集配体系统适配体
PLoS One. 2014 Mar 6;9(6):e90752. doi: 10.1371/journal.pone.0090752. eCollection 2014.
5
[Cell-ELA-based determination of binding affinity of DNA aptamer against U87-EGFRvIII cell].基于细胞-酶联免疫吸附测定法检测DNA适配体与U87-EGFRvIII细胞的结合亲和力
Sheng Wu Gong Cheng Xue Bao. 2013 May;29(5):664-71.
6
Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.靶向表皮生长因子受体变体Ⅲ(EGFRvIII)突变体的适体可抑制其组成型自磷酸化,并影响胶质母细胞瘤细胞的迁移、侵袭和增殖。
Oncotarget. 2015 Nov 10;6(35):37570-87. doi: 10.18632/oncotarget.6066.
7
Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor Therapy.靶向ERBB2受体酪氨酸激酶的适体在肿瘤治疗中的应用
Methods Mol Biol. 2015;1317:3-15. doi: 10.1007/978-1-4939-2727-2_1.
8
CS-SELEX generates high-affinity ssDNA aptamers as molecular probes for hepatitis C virus envelope glycoprotein E2.CS-SELEX 产生高亲和力的 ssDNA 适体作为丙型肝炎病毒包膜糖蛋白 E2 的分子探针。
PLoS One. 2009 Dec 3;4(12):e8142. doi: 10.1371/journal.pone.0008142.
9
Inhibition of cell proliferation by an anti-EGFR aptamer.抗 EGFR 适体抑制细胞增殖。
PLoS One. 2011;6(6):e20299. doi: 10.1371/journal.pone.0020299. Epub 2011 Jun 8.
10
Discovering aptamers by cell-SELEX against human soluble growth factors ectopically expressed on yeast cell surface.通过细胞指数富集的配体系统进化技术(cell-SELEX)筛选针对在酵母细胞表面异位表达的人可溶性生长因子的适体。
PLoS One. 2014 Mar 27;9(3):e93052. doi: 10.1371/journal.pone.0093052. eCollection 2014.

引用本文的文献

1
Diagnostic and Therapeutic Aptamers: A Promising Pathway to Improved Cardiovascular Disease Management.诊断和治疗性适体:改善心血管疾病管理的一条充满希望的途径。
JACC Basic Transl Sci. 2023 Sep 27;9(2):260-277. doi: 10.1016/j.jacbts.2023.06.013. eCollection 2024 Feb.
2
Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer.使用抗表皮生长因子受体(EGFR)RNA适配体靶向治疗具有临床相关EGFR突变的肺癌。
Mol Ther Nucleic Acids. 2023 Oct 4;34:102046. doi: 10.1016/j.omtn.2023.102046. eCollection 2023 Dec 12.
3
Unravelling the Glioblastoma Tumour Microenvironment: Can Aptamer Targeted Delivery Become Successful in Treating Brain Cancers?解析胶质母细胞瘤肿瘤微环境:适体靶向递送能否成功用于治疗脑癌?
Cancers (Basel). 2023 Sep 1;15(17):4376. doi: 10.3390/cancers15174376.
4
Aptasensors Are Conjectured as Promising ALT and AST Diagnostic Tools for the Early Diagnosis of Acute Liver Injury.适配体传感器被认为是用于急性肝损伤早期诊断的有前景的谷丙转氨酶和谷草转氨酶诊断工具。
Life (Basel). 2023 May 29;13(6):1273. doi: 10.3390/life13061273.
5
Therapeutic Potential of Aptamer-Protein Interactions.适体-蛋白质相互作用的治疗潜力。
ACS Pharmacol Transl Sci. 2022 Nov 4;5(12):1211-1227. doi: 10.1021/acsptsci.2c00156. eCollection 2022 Dec 9.
6
Aptamers and antibodies: rivals or allies in cancer targeted therapy?适体与抗体:癌症靶向治疗中的对手还是盟友?
Explor Target Antitumor Ther. 2021;2(1):107-121. doi: 10.37349/etat.2021.00035. Epub 2021 Feb 28.
7
Aptamers: Potential Diagnostic and Therapeutic Agents for Blood Diseases.适体:血液疾病的潜在诊断和治疗剂。
Molecules. 2022 Jan 7;27(2):383. doi: 10.3390/molecules27020383.
8
A comparative analysis of cell surface targeting aptamers.细胞表面靶向适体的比较分析。
Nat Commun. 2021 Nov 1;12(1):6275. doi: 10.1038/s41467-021-26463-w.
9
SELEX: Critical factors and optimization strategies for successful aptamer selection.SELEX:成功的适体筛选的关键因素和优化策略。
Biotechnol Appl Biochem. 2022 Oct;69(5):1771-1792. doi: 10.1002/bab.2244. Epub 2021 Sep 3.
10
Improving Breast Cancer Treatment Specificity Using Aptamers Obtained by 3D Cell-SELEX.利用通过三维细胞指数富集配体系统进化技术获得的适体提高乳腺癌治疗的特异性
Pharmaceuticals (Basel). 2021 Apr 9;14(4):349. doi: 10.3390/ph14040349.

本文引用的文献

1
Targeting inhibition of GluR1 Ser845 phosphorylation with an RNA aptamer that blocks AMPA receptor trafficking.用一种阻断AMPA受体转运的RNA适体靶向抑制GluR1 Ser845磷酸化。
J Neurochem. 2009 Jan;108(1):147-57. doi: 10.1111/j.1471-4159.2008.05748.x. Epub 2008 Nov 12.
2
Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers.用适配体靶向血管性血友病因子的解毒剂控制血小板抑制。
Oligonucleotides. 2007 Fall;17(3):265-74. doi: 10.1089/oli.2007.0089.
3
NF-kappaB inhibition by an adenovirus expressed aptamer sensitizes TNFalpha-induced apoptosis.腺病毒表达的适配体对核因子-κB的抑制作用可增强肿瘤坏死因子α诱导的细胞凋亡。
Biochem Biophys Res Commun. 2007 Aug 3;359(3):475-80. doi: 10.1016/j.bbrc.2007.05.125. Epub 2007 May 25.
4
Regulation of {alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor trafficking through PKA phosphorylation of the Glu receptor 1 subunit.通过蛋白激酶A对谷氨酸受体1亚基的磷酸化作用调控α-氨基-3-羟基-5-甲基-4-异恶唑丙酸受体的转运
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3579-84. doi: 10.1073/pnas.0611698104. Epub 2007 Feb 21.
5
Gene therapy progress and prospects: RNA aptamers.基因治疗的进展与前景:RNA适配体
Gene Ther. 2007 Feb;14(4):283-91. doi: 10.1038/sj.gt.3302900.
6
Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII.残基Y1045的低磷酸化导致EGFRvIII的下调缺陷。
Cancer Biol Ther. 2006 Oct;5(10):1361-8. doi: 10.4161/cbt.5.10.3226. Epub 2006 Oct 26.
7
Aptamers come of age - at last.适体终于走向成熟。
Nat Rev Microbiol. 2006 Aug;4(8):588-96. doi: 10.1038/nrmicro1458.
8
Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial.使用人源化抗表皮生长因子受体(EGFR)抗体h-R3治疗高级别胶质瘤患者:一项I/II期试验的报告。
Cancer Biol Ther. 2006 Apr;5(4):375-9. doi: 10.4161/cbt.5.4.2522. Epub 2006 Apr 19.
9
HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.用于治疗多形性胶质母细胞瘤的HER1/EGFR酪氨酸激酶抑制剂
J Neurooncol. 2005 Aug;74(1):77-86. doi: 10.1007/s11060-005-0603-7.
10
Production and N-glycan analysis of secreted human erythropoietin glycoprotein in stably transfected Drosophila S2 cells.稳定转染的果蝇S2细胞中分泌型人促红细胞生成素糖蛋白的生产及N-聚糖分析
Biotechnol Bioeng. 2005 Nov 20;92(4):452-61. doi: 10.1002/bit.20605.